Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood clot and a skin filler fix receding gums?

NCT ID NCT07662447

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding hyaluronic acid to a platelet-rich fibrin membrane improves the treatment of receding gums. Thirty adults with a specific type of gum recession will receive either the PRF membrane alone or with hyaluronic acid, alongside a surgical flap procedure. The main goal is to see how much of the exposed tooth root is covered, and secondary goals include measuring pain after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich fibrin and hyaluronic acid
What this could lead to
If successful, this could offer a more effective, less painful treatment for receding gums using the body's own healing factors.
What could go wrong
This is a small, early-stage trial with only 30 participants, so results may not apply to everyone. The added benefit of hyaluronic acid over PRF alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Systemically healthy patients aged 18-50 years presenting with Cairo RT1 gingival recession defects were included in the study. Patients were selected if the recession defect was present on a vital tooth with an identifiable cementoenamel junction and no interproximal clinical attachment loss. The selected tooth was required to be free from caries, cervical restorations, non-carious cervical lesions interfering with measurement, pulpal pathology, and pathological mobility. Patients with acceptable oral hygiene after initial periodontal therapy, preferably with Plaque Index ≤1, were included. Patients willing to participate in the study, sign informed consent, and report for all follow-up visits were included. -Exclusion Criteria Patients were excluded if they were smokers or tobacco users, including smokeless tobacco users. Patients with systemic conditions that could affect periodontal wound healing, such as uncontrolled diabetes mellitus, immunosuppressive disorders, bleeding disorders, connective tissue disorders, or any serious systemic illness, were not included. Pregnant or lactating women were excluded from the study. Patients taking medications known to influence gingival healing, including corticosteroids, immunosuppressants, bisphosphonates, anticoagulants, or long-term anti-inflammatory drugs, were excluded. Patients with poor oral hygiene, untreated gingival inflammation, active periodontal disease, or recession defects classified as Cairo RT2 or RT3 were not included. Teeth with cervical caries, cervical restorations, deep abrasion, erosion, non-carious cervical lesions interfering with CEJ identification, endodontic pathology, periapical lesions, non-vital pulp, traumatic occlusion that could not be corrected before surgery, or previous periodontal plastic surgery at the selected site within the past 12 months were excluded. Patients undergoing orthodontic treatment or those who had recently completed orthodontic treatment were also excluded if tooth movement could affect gingival margin stability. Patients unwilling to provide consent or unable to attend the follow-up schedule were not included.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gingival recession are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gulf Medical University

    Ajman, Ajman Emirate, 00000, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.